Skip to main content
Genprex, Inc. logo

Genprex, Inc. — Investor Relations & Filings

Ticker · GNPX ISIN · US3724461047 LEI · 549300KS9771JZ234890 US Professional, scientific and technical activities
Open in API
Filings indexed 468 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country US United States of America
Listing US GNPX

About Genprex, Inc.

https://www.genprex.com/

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapeutic options for large patient populations. Its oncology pipeline includes clinical-stage programs for lung cancer, such as the Acclaim-3 trial in small cell lung cancer (SCLC) and other programs for non-small cell lung cancer (NSCLC). In addition to its cancer programs, Genprex is developing gene therapies for diabetes. The company utilizes a proprietary, non-viral nanoparticle delivery system to systemically deliver therapeutic genes.

Recent filings

Filing Released Lang Actions
FORM S-3
Regulatory Filings Classification · 85% confidence The document is a Form S-3 registration statement and prospectus filed with the SEC under the Securities Act of 1933, detailing a shelf registration of various securities. It is not an annual or interim report, earnings release, proxy, or director transaction disclosure, but a regulatory registration filing for securities offerings. Under the taxonomy, such SEC registration statements and accompanying prospectuses fall under general regulatory filings (RNS).
2026-06-05 English
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act of 1934. It provides information about an “Other Event” press release and exhibits but does not itself constitute an annual, interim, earnings or ESG report, nor is it announcing a meeting vote or management change. It is a regulatory filing, so it falls into the catch-all Regulatory Filings category (RNS).
2026-05-26 English
FORM 8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K current report filed under the Securities Exchange Act of 1934. It contains an "Item 8.01 Other Events" disclosure of a press release regarding preclinical data presentation and forward-looking statements, with no substantive financial statements, management changes, dividends, earnings metrics, or M&A content. It does not meet the criteria for earnings release, quarterly report, manager changes, or any specialized category. Therefore, it falls under the general regulatory announcement/fallback category.
2026-05-14 English
8-K - Genprex, Inc. (0001595248) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 30, 2026. It announces a patent grant by the Israel Patent Office related to the company's gene therapy product, which is a significant corporate event but not a financial report. The document includes forward-looking statements and a signature by the CEO/CFO. There are no financial statements or detailed financial data presented. The document is an event announcement rather than a full report like an Annual Report (10-K) or Interim Report (IR). It does not fit into categories like Earnings Release, Management Reports, or Capital Updates. It is a regulatory filing reporting a material event, so it falls under Regulatory Filings (RNS). The document length (8045 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2026-04-30 English
8-K - Genprex, Inc. (0001595248) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 28, 2026. It announces a press release about positive preclinical data on a diabetes gene therapy drug candidate to be presented at an upcoming scientific meeting. The content focuses on a research update and forward-looking statements about the company's development programs and future prospects. There are no financial statements or detailed financial data included. The document is primarily an event announcement and press release disclosure rather than a financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a proxy, voting results, or governance document. Given the nature of the filing (Form 8-K) and the content being an announcement of other events and press releases, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2026-04-28 English
8-K - Genprex, Inc. (0001595248) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing by Genprex, Inc. It contains two primary items: Item 7.01, which announces an investor presentation (Exhibit 99.1), and Item 8.01, which provides an update on a new Sponsored Research Agreement and clinical trial progress. While it mentions an investor presentation, the document itself is a regulatory filing (Form 8-K) that provides substantive updates on company operations and research, rather than just being a notification of a report's availability. Under the provided definitions, Form 8-K filings that disclose material events are classified as Regulatory Filings (RNS).
2026-04-21 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.